Sugi Predict

Sugi Predict / Targets / MAPKAPK5

MAPKAPK5

MAP kinase-activated protein kinase 5 · Q8IW41 · MAPKAPK5 on Sugi Atlas →

15,112 patent compounds predicted against MAPKAPK5, 9,200 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1477008 SCHEMBL1477008 0.72 16/20
SCHEMBL1477550 SCHEMBL1477550 0.71 16/20
SCHEMBL1476125 SCHEMBL1476125 0.75 15/20
SCHEMBL1476797 SCHEMBL1476797 0.73 15/20
SCHEMBL1476141 SCHEMBL1476141 0.51 15/20
SCHEMBL1477011 SCHEMBL1477011 1.00 14/20
SCHEMBL1475717 SCHEMBL1475717 0.86 14/20
SCHEMBL1476692 SCHEMBL1476692 0.73 14/20
SCHEMBL1476354 SCHEMBL1476354 0.70 14/20
SCHEMBL1476403 SCHEMBL1476403 0.70 14/20
SCHEMBL1477930 SCHEMBL1477930 0.64 14/20
SCHEMBL1570223 SCHEMBL1570223 0.63 14/20
SCHEMBL1475901 SCHEMBL1475901 1.00 13/20
SCHEMBL1570261 SCHEMBL1570261 0.70 13/20
SCHEMBL1570184 SCHEMBL1570184 0.66 13/20
SCHEMBL1570202 SCHEMBL1570202 0.64 13/20
SCHEMBL1570335 SCHEMBL1570335 0.64 13/20
SCHEMBL1476876 SCHEMBL1476876 0.61 13/20
SCHEMBL1476062 SCHEMBL1476062 0.60 13/20
SCHEMBL1476303 SCHEMBL1476303 0.53 13/20

Clinical trials — most relevant to MAPKAPK5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Molecular Mechanisms of Type 2 Diabetes Mellitus PHASE4COMPLETED
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Clinical Evaluation of the Effect of Metformin in Sepsis PHASE3UNKNOWN
Effects of p38 Inhibitor AZD7624 in Corticosteroid Resistant Asthma PHASE2COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS PHASE2COMPLETED
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... PHASE2COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma PHASE2COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule PHASE2NOT_YET_RECRUITING
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant PHASE2RECRUITING
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma PHASE2COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy Study EARLY_PHASE1NOT_YET_RECRUITING
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
p38 Mitogen-Activated Protein Kinase (MAPK) and Steroid Insensitivity in Asthma nanCOMPLETED
Study of Metabolic Modifications in Children With Noonan Syndrome nanCOMPLETED
Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer nanUNKNOWN
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Exercise in Type 1 Diabetes Mellitus nanCOMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies nanUNKNOWN
Blood Flow Responses to an Oral Glucose Tolerance Test in Type 2 Diabetes nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MAPKAPK5 binder may also engage these)

ProteinNameSimilarity
O54992 — 1.000 O54992 →
Q91821 — 0.978 Q91821 →
Q28GW8 — 0.977 Q28GW8 →
P62205 — 0.977 P62205 →
P32866 — 0.976 P32866 →
O54785 — 0.975 O54785 →
PLK2 Serine/threonine-protein kinase PLK2 0.975 landscape →
NEK2 Serine/threonine-protein kinase Nek2 0.975 landscape →
Q8BPM2 — 0.974 Q8BPM2 →
LIMK2 LIM domain kinase 2 0.974 landscape →
P49187 — 0.974 P49187 →
MELK Maternal embryonic leucine zipper kinase 0.974 landscape →
Q9WVL4 — 0.974 Q9WVL4 →
F1QGZ6 — 0.973 F1QGZ6 →
Q5R4L1 — 0.973 Q5R4L1 →
A7MBL8 — 0.972 A7MBL8 →
Q62073 — 0.972 Q62073 →
RAPGEF4 Rap guanine nucleotide exchange factor 4 0.972 landscape →
Q07139 — 0.972 Q07139 →
P53666 — 0.971 P53666 →
A2VDU3 — 0.971 A2VDU3 →
P70032 — 0.971 P70032 →
MAP4K5 Mitogen-activated protein kinase kinase kinase kinase 5 0.971 landscape →
Q9H8V3 — 0.971 Q9H8V3 →
Q21029 — 0.971 Q21029 →
Q9ESL4 — 0.970 Q9ESL4 →
J9W0G9 — 0.970 J9W0G9 →
Q6NU47 — 0.970 Q6NU47 →
O35099 — 0.970 O35099 →
MAPK10 Mitogen-activated protein kinase 10 0.970 landscape →